Clinical Study
Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?
Table 3
Details of multivariate analysis for progression-free survival.
| Variable | Hazard ratio | value on Cox regression analysis |
| | 1.710 (0.486–6.019) | 0.430 | ECOG PS | 0.354 (0.98–1.288) | 0.115 | Smoking status | 1.474 (0.671–3.239) | 0.334 | Brain metastasis | 0.932 (0.416–2.090) | 0.865 | EGFR mutation type | 0.563 (0.272–1.164) | 0.121 |
|
|
was defined as age of 65 years or above.
|